Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Prospective Design of Anti-Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain.

Kanodia JS, Gadkar K, Bumbaca D, Zhang Y, Tong RK, Luk W, Hoyte K, Lu Y, Wildsmith KR, Couch JA, Watts RJ, Dennis MS, Ernst JA, Scearce-Levie K, Atwal JK, Ramanujan S, Joseph S.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):283-91. doi: 10.1002/psp4.12081. Epub 2016 May 17.

2.

Characterization of a sensitive mouse Aβ40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice.

Lu Y, Hoyte K, Montgomery WH, Luk W, He D, Meilandt WJ, Zuchero YJ, Atwal JK, Scearce-Levie K, Watts RJ, DeForge LE.

Bioanalysis. 2016 May;8(10):1067-75. doi: 10.4155/bio-2016-0003. Epub 2016 Apr 20.

PMID:
27094761
3.

Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies.

Zuchero YJ, Chen X, Bien-Ly N, Bumbaca D, Tong RK, Gao X, Zhang S, Hoyte K, Luk W, Huntley MA, Phu L, Tan C, Kallop D, Weimer RM, Lu Y, Kirkpatrick DS, Ernst JA, Chih B, Dennis MS, Watts RJ.

Neuron. 2016 Jan 6;89(1):70-82. doi: 10.1016/j.neuron.2015.11.024. Epub 2015 Dec 10.

4.

Lack of Widespread BBB Disruption in Alzheimer's Disease Models: Focus on Therapeutic Antibodies.

Bien-Ly N, Boswell CA, Jeet S, Beach TG, Hoyte K, Luk W, Shihadeh V, Ulufatu S, Foreman O, Lu Y, DeVoss J, van der Brug M, Watts RJ.

Neuron. 2015 Oct 21;88(2):289-97. doi: 10.1016/j.neuron.2015.09.036.

5.

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.

Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, Bumbaca D, Gadkar K, Hoyte K, Luk W, Lu Y, Ernst JA, Scearce-Levie K, Couch JA, Dennis MS, Watts RJ.

Sci Transl Med. 2014 Nov 5;6(261):261ra154. doi: 10.1126/scitranslmed.3009835.

6.

Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier.

Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia BA, Nguyen Q, Lin Y, Lin Z, Balazs M, Scearce-Levie K, Ernst JA, Dennis MS, Watts RJ.

Sci Transl Med. 2013 May 1;5(183):183ra57, 1-12. doi: 10.1126/scitranslmed.3005338.

7.

A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K.

Nature. 2012 Aug 2;488(7409):96-9. doi: 10.1038/nature11283.

PMID:
22801501
8.

Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.

Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, Prabhu S.

MAbs. 2012 Jan-Feb;4(1):101-9. doi: 10.4161/mabs.4.1.18543.

9.

Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.

Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS.

Sci Transl Med. 2011 May 25;3(84):84ra44. doi: 10.1126/scitranslmed.3002230.

10.

A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.

Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ.

Sci Transl Med. 2011 May 25;3(84):84ra43. doi: 10.1126/scitranslmed.3002254.

11.

Components of speech prosody and their use in detection of syntactic structure by older adults.

Hoyte KJ, Brownell H, Wingfield A.

Exp Aging Res. 2009 Jan-Mar;35(1):129-51. doi: 10.1080/03610730802565091.

12.
13.

Cellular laserfection.

Rhodes K, Clark I, Zatcoff M, Eustaquio T, Hoyte KL, Koller MR.

Methods Cell Biol. 2007;82:309-33.

PMID:
17586262
14.

Variable solutions to the same problem: aberrant practice effects in object naming by three aphasic patients.

Wingfield A, Brownell H, Hoyte KJ.

Brain Lang. 2006 Jun;97(3):351-6. Epub 2005 Dec 28.

PMID:
16386289
15.

Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.

Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG, Haywood LJ, Hoyte K, Kaufman ES, Kim MH, Nasco E, Waldo AL; National Heart, Lung, and Blood Institute AFFIRM Investigators.

Arch Intern Med. 2005 May 23;165(10):1185-91.

PMID:
15911734
16.

Transgenic overexpression of dystroglycan does not inhibit muscular dystrophy in mdx mice.

Hoyte K, Jayasinha V, Xia B, Martin PT.

Am J Pathol. 2004 Feb;164(2):711-8.

17.

Inhibition of dystroglycan cleavage causes muscular dystrophy in transgenic mice.

Jayasinha V, Nguyen HH, Xia B, Kammesheidt A, Hoyte K, Martin PT.

Neuromuscul Disord. 2003 Jun;13(5):365-75.

PMID:
12798792
18.

Overexpression of the CT GalNAc transferase inhibits muscular dystrophy in a cleavage-resistant dystroglycan mutant mouse.

Jayasinha V, Hoyte K, Xia B, Martin PT.

Biochem Biophys Res Commun. 2003 Mar 21;302(4):831-6.

PMID:
12646245
21.

Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice.

Nguyen HH, Jayasinha V, Xia B, Hoyte K, Martin PT.

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5616-21.

22.

Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression.

Xia B, Hoyte K, Kammesheidt A, Deerinck T, Ellisman M, Martin PT.

Dev Biol. 2002 Feb 1;242(1):58-73.

23.

Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness.

Buchan AM, Barber PA, Newcommon N, Karbalai HG, Demchuk AM, Hoyte KM, Klein GM, Feasby TE.

Neurology. 2000 Feb 8;54(3):679-84.

PMID:
10680803
24.

Effect of L-tryptophan on spasmodic torticollis.

Lal S, Young SN, Kiely ME, Hoyte K, Baxter DW, Sourkes TL.

Can J Neurol Sci. 1981 Nov;8(4):305-8.

PMID:
6459839
25.

Immunoreactive and biologically active somatostatin-like material in the human retina.

Rorstad OP, Senterman MK, Hoyte KM, Martin JB.

Brain Res. 1980 Oct 20;199(2):488-92. No abstract available.

PMID:
6106523
26.
27.
28.

Distribution of somatostatin in rat brain.

Epelbaum J, Martin JB, Brazeau P, Willoughby J, Hoyte K.

Trans Am Neurol Assoc. 1977;102:87-90. No abstract available.

PMID:
616123
29.

Supplemental Content

Support Center